Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Myelofibrosis Market Will Exceed $1B by 2025

By James Beggs, Ph.D., Oncology and Hematology Analyst, GlobalData | November 30, 2016

The myelofibrosis market is expected to almost double in value from $545.2 million in 2015 to $1.02 billion by 2025, representing a compound annual growth rate of 6.4%, according to research and consulting firm GlobalData.

The company’s latest report states that the strength of this growth, which covers the seven major markets (7MM) of the US, France, Germany, Italy, Spain, the UK, and Japan, will primarily be driven by the launch of pipeline agents, including Gilead’s momelotinib, Promedior’s PRM-151, and Johnson & Johnson/Geron’s imetelstat. Other factors include an increase in the incidence of myelofibrosis, and a rise in the use of drugs for the treatment of splenomegaly and constitutional symptoms.

James Beggs, Ph.D., GlobalData’s Analyst covering Oncology and Hematology, explains: “Incyte/Novartis’ Jakafi is currently the only drug approved for the treatment of myelofibrosis-associated splenomegaly and constitutional symptoms in the 7MM. Currently, there are no drugs approved for patients who are refractory or become unresponsive to Jakafi treatment, and momelotinib and imetelstat are expected to contribute towards addressing this issue with launches in the second-line setting in 2017 and 2021, respectively.”

Despite this rising competition from pipeline agents, Jakafi is expected to retain its leading spot in the market, with just over 50% of the market share in 2025. GlobalData expects that momelotinib can ultimately only capture about 25% of Jakafi’s patient share in the first-line setting, as Jakafi has the first-to-market advantage, and long-term efficacy and safety data are available.

Beggs continues: “Imetelstat, a first-in-class telomerase inhibitor, is expected to struggle for market penetration due to late market entry and the high level of toxicity shown in previous clinical trials. GlobalData estimates sales of the drug in 2025 to be only $21.2 million, representing just 2% of the myelofibrosis market in the 7MM.

“PRM-151, however, looks more promising in terms of expected sales. If the drug manages to demonstrate anti-fibrotic effects in myelofibrosis patients in a pivotal trial, it may reduce patients’ dependency on treatments for anemia, splenomegaly, and constitutional symptoms, thereby fulfilling unmet needs. In effect, it will potentially limit the growth of other drug classes in the myelofibrosis landscape.”


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE